Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Clinical evidence

OP-1250-001

68 evidence topics · 8 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using dose-limiting toxicity as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline characteristics at 60 and 120 mg/day
Characteristic60 mg (n = 30)120 mg (n = 86)Total (N = 116)
Age, years; median (range)“59.5 (30–81)”View highlighted excerpt for this quote“61.0 (32–85)”View highlighted excerpt for this quote“61.0 (30–85)”View highlighted excerpt for this quote
Female, n (%)“30 (100)”View highlighted excerpt for this quote“86 (100)”View highlighted excerpt for this quote“116 (100)”View highlighted excerpt for this quote
White, n (%)“23 (76.7)”View highlighted excerpt for this quote“70 (81.4)”View highlighted excerpt for this quote“93 (80.2)”View highlighted excerpt for this quote
Black or African American, n (%)“1 (3.3)”View highlighted excerpt for this quote“7 (8.1)”View highlighted excerpt for this quote“8 (6.9)”View highlighted excerpt for this quote
Asian, n (%)“1 (3.3)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“4 (3.4)”View highlighted excerpt for this quote
Race not reported or other, n (%)“5 (16.7)”View highlighted excerpt for this quote“6 (7.0)”View highlighted excerpt for this quote“11 (9.5)”View highlighted excerpt for this quote
Childbearing potential, n (%)“0”View highlighted excerpt for this quote“7 (8.1)”View highlighted excerpt for this quote“7 (6.0)”View highlighted excerpt for this quote
ECOG performance status 0, n (%)“19 (63.3)”View highlighted excerpt for this quote“46 (53.5)”View highlighted excerpt for this quote“65 (56.0)”View highlighted excerpt for this quote
ECOG performance status 1, n (%)“11 (36.7)”View highlighted excerpt for this quote“40 (46.5)”View highlighted excerpt for this quote“51 (44.0)”View highlighted excerpt for this quote
Measurable disease, n (%)“29 (96.7)”View highlighted excerpt for this quote“69 (80.2)”View highlighted excerpt for this quote“98 (84.5)”View highlighted excerpt for this quote
Visceral disease, n (%)“24 (80.0)”View highlighted excerpt for this quote“61 (70.9)”View highlighted excerpt for this quote“85 (73.3)”View highlighted excerpt for this quote
1 prior line of therapy in advanced setting, n (%)“9 (30)”View highlighted excerpt for this quote“21 (24.4)”View highlighted excerpt for this quote“30 (25.9)”View highlighted excerpt for this quote
2 prior lines of therapy in advanced setting, n (%)“6 (20.0)”View highlighted excerpt for this quote“29 (33.7)”View highlighted excerpt for this quote“35 (30.2)”View highlighted excerpt for this quote
3 prior lines of therapy in advanced setting, n (%)“6 (20.0)”View highlighted excerpt for this quote“19 (22.1)”View highlighted excerpt for this quote“25 (21.6)”View highlighted excerpt for this quote
4 prior lines of therapy in advanced setting, n (%)“6 (20.0)”View highlighted excerpt for this quote“10 (11.6)”View highlighted excerpt for this quote“16 (13.8)”View highlighted excerpt for this quote
5 or more prior lines of therapy in advanced setting, n (%)“3 (10.0)”View highlighted excerpt for this quote“7 (8.1)”View highlighted excerpt for this quote“10 (8.6)”View highlighted excerpt for this quote
1 prior line of endocrine therapy in advanced setting, n (%)“12 (40.0)”View highlighted excerpt for this quote“30 (34.9)”View highlighted excerpt for this quote“42 (36.2)”View highlighted excerpt for this quote
2 prior lines of endocrine therapy in advanced setting, n (%)“7 (23.3)”View highlighted excerpt for this quote“32 (37.2)”View highlighted excerpt for this quote“39 (33.6)”View highlighted excerpt for this quote
3 prior lines of endocrine therapy in advanced setting, n (%)“7 (23.3)”View highlighted excerpt for this quote“15 (17.4)”View highlighted excerpt for this quote“22 (19.0)”View highlighted excerpt for this quote
4 prior lines of endocrine therapy in advanced setting, n (%)“3 (10.0)”View highlighted excerpt for this quote“8 (9.3)”View highlighted excerpt for this quote“11 (9.5)”View highlighted excerpt for this quote
5 prior lines of endocrine therapy in advanced setting, n (%)“1 (3.3)”View highlighted excerpt for this quote“1 (1.2)”View highlighted excerpt for this quote“2 (1.7)”View highlighted excerpt for this quote
Prior CDK4/6 inhibitor, n (%)“28 (93.3)”View highlighted excerpt for this quote“83 (96.5)”View highlighted excerpt for this quote“111 (95.7)”View highlighted excerpt for this quote
Prior aromatase inhibitor, n (%)“23 (76.7)”View highlighted excerpt for this quote“73 (84.9)”View highlighted excerpt for this quote“96 (82.8)”View highlighted excerpt for this quote
Prior fulvestrant, n (%)“19 (63.3)”View highlighted excerpt for this quote“57 (66.3)”View highlighted excerpt for this quote“76 (65.5)”View highlighted excerpt for this quote
Prior chemotherapy, n (%)“12 (40.0)”View highlighted excerpt for this quote“27 (31.4)”View highlighted excerpt for this quote“39 (33.6)”View highlighted excerpt for this quote
ESR1 mutations (ctDNA) at baseline, n/N (%)“15/21 (71.4)”View highlighted excerpt for this quote“36/75 (48.0)”View highlighted excerpt for this quote“51/96 (53.1)”View highlighted excerpt for this quote
Efficacy results
Response and clinical benefit by dose level
Endpoint60 mg/day120 mg/day
Response-evaluable participants with measurable disease“(n = 26)”View highlighted excerpt for this quote“66 response-evaluable patients treated with 120 mg/day palazestrant”View highlighted excerpt for this quote
Confirmed partial responses“2 confirmed PRs (cPRs; 7.7%)”View highlighted excerpt for this quote“3 confirmed PRs (4.5%)”View highlighted excerpt for this quote
Unconfirmed partial responses“1 unconfirmed PR (3.8%)”View highlighted excerpt for this quote“2 unconfirmed PRs (3.0%)”View highlighted excerpt for this quote
All partial responses“a total of 3 PRs (11.5%)”View highlighted excerpt for this quote“a total of 5 PRs (7.6%)”View highlighted excerpt for this quote
Clinical benefit rate, all evaluable participants“19.2% (95% CI, 6.6–39.4)”View highlighted excerpt for this quote“45.7% (95% CI, 33.7–58.1)”View highlighted excerpt for this quote
Participants evaluable for clinical benefit rate“(n = 26)”View highlighted excerpt for this quote“(n = 70)”View highlighted excerpt for this quote
Clinical benefit rate, ESR1 mutation“23.1% (95% CI, 5.0–53.8)”View highlighted excerpt for this quote“58.6% (95% CI, 38.9–76.5)”View highlighted excerpt for this quote
Participants with ESR1 mutation evaluable for clinical benefit rate“among the 13 patients with cancers with ESR1 mutations”View highlighted excerpt for this quote“(n = 29)”View highlighted excerpt for this quote
Second- or third-line subset at 120 mg (conference presentation)
PopulationMedian PFS, months [95% CI]6-month PFSCBR
All participants (n=86)“4.6 [3.5, 6.5]”“38%”“40%”
Second or third line with or without chemotherapy (n=49)“7.2 [3.7, 7.8]”“54%”“48%”
ESR1 mutation (n=36)“5.6 [3.7, 7.8]”“46%”“52%”
ESR1 mutation, second or third line with or without chemotherapy (n=23)“7.3 [5.0, NA]”“62%”“59%”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events occurring in at least 15% of participants, n (%)
Event60 mg any grade (n = 30)60 mg grade 360 mg grade 4120 mg any grade (n = 86)120 mg grade 3120 mg grade 4
TEAE: nausea“14 (46.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“54 (62.8)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: vomiting“5 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“25 (29.1)”View highlighted excerpt for this quote“4 (4.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: fatigue“13 (43.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“22 (25.6)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: neutropenia“2 (6.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“21 (24.4)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“6 (7.0)”View highlighted excerpt for this quote
TEAE: headache“7 (23.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“17 (19.8)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: constipation“6 (20.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“15 (17.4)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: diarrhea“6 (20.0)”View highlighted excerpt for this quote“1 (3.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“12 (14.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: nausea“10 (33.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“47 (54.7)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: vomiting“3 (10.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“21 (24.4)”View highlighted excerpt for this quote“2 (2.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: fatigue“9 (30.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“17 (19.8)”View highlighted excerpt for this quote“2 (2.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: neutropenia“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“18 (20.9)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“5 (5.8)”View highlighted excerpt for this quote
TRAE: headache“3 (10.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“13 (15.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Aspartate aminotransferase increase at 120 mg (conference presentation, N=83)
EventGrade 1Grade 2Grade 3Grade 4All, n (%)
AST increased“10”“2”“1”“0”“13 (16)”
Study limitations
Summary

OP-1250-001 was an open-label phase 1/2 study without a comparator arm, which the authors state limits interpretation of the safety profile and antitumor activity. Efficacy estimates come from dose cohorts of 30 participants at 60 mg/day and 86 at 120 mg/day, and only 6 participants were enrolled at 90 mg/day, during dose escalation. Response and CBR analyses used restricted populations: response required measurable disease and a postbaseline assessment (66 response-evaluable participants at 120 mg/day), and the CBR analysis excluded participants who discontinued without radiographic progression within 24 weeks. Two reports of the 120 mg cohort give different values: the peer-reviewed publication reports a CBR of 45.7% in 70 evaluable participants and a median PFS of 4.8 months, and the 2023 conference presentation reports a CBR of 40% (32/81) and a median PFS of 4.6 months. The study excluded primary endocrine resistance; fasted dosing, the exclusion of proton pump inhibitors and most common antiemetics, and a relatively large capsule may have increased gastrointestinal events. The central nervous system metastases cohort is not included in the publication, and the association between ESR1 mutation reduction and CBR is based on 11 and 32 participants (CBR 73% [8/11] versus 25% [8/32]). All 116 participants treated at 60 or 120 mg/day were women, 33.6% had received prior chemotherapy, and 8.6% had received 5 or more prior lines of therapy in the advanced setting.